These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9662203)

  • 21. Key issues for a potential human immunodeficiency virus vaccine.
    Hu DJ; Vitek CR; Bartholow B; Mastro TD
    Clin Infect Dis; 2003 Mar; 36(5):638-44. PubMed ID: 12594646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Design, development and successful application of safe and effective HIV therapeutic and prophylactic vaccines].
    Abalaka JO
    Zhonghua Nan Ke Xue; 2005 Jan; 11(1):8-16. PubMed ID: 15704674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda.
    Gray RH; Li X; Kigozi G; Serwadda D; Nalugoda F; Watya S; Reynolds SJ; Wawer M
    AIDS; 2007 Apr; 21(7):845-50. PubMed ID: 17415039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A small dose of HIV? HIV vaccine mental models and risk communication.
    Newman PA; Seiden DS; Roberts KJ; Kakinami L; Duan N
    Health Educ Behav; 2009 Apr; 36(2):321-33. PubMed ID: 18032589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paralysis in AIDS vaccine development violates ethical principles and human rights.
    Mann JM
    J Int Assoc Physicians AIDS Care; 1998 May; 4(5):42-3. PubMed ID: 11365188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine.
    Lampinen TM; Chan K; Remis RS; Merid MF; Rusch M; Vincelette J; Logue K; Popovic V; Alary M; Schechter MT; Hogg RS
    CMAJ; 2005 Feb; 172(4):479-83. PubMed ID: 15710939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is there an epidemic of HIV Infection in the US ESRD program?
    Eggers PW; Kimmel PL
    J Am Soc Nephrol; 2004 Sep; 15(9):2477-85. PubMed ID: 15339998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing HIV. Part 8: Controlling an epidemic. 8.3 Prospects for a preventive HIV vaccine.
    Kent SJ; Clancy RL; Ada GL
    Med J Aust; 1996 Aug; 165(4):212-5. PubMed ID: 8773653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda.
    Gray RH; Li X; Wawer MJ; Gange SJ; Serwadda D; Sewankambo NK; Moore R; Wabwire-Mangen F; Lutalo T; Quinn TC;
    AIDS; 2003 Sep; 17(13):1941-51. PubMed ID: 12960827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Joint inferences on vaccine efficacy against infection and disease with application to the first HIV vaccine efficacy trial.
    Cai T; Gilbert PB; Self SG
    J Biopharm Stat; 2006; 16(4):517-38. PubMed ID: 16892911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Model-based optimization of infectivity parameters: a study of the early epidemic in San Francisco.
    Ahlgren DJ; Gorny MK; Stein AC
    J Acquir Immune Defic Syndr (1988); 1990; 3(6):631-43. PubMed ID: 2338619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Threshold conditions for the spread of the HIV infection in age-structured populations of homosexual men.
    Hyman JM; Li J; Stanley EA
    J Theor Biol; 1994 Jan; 166(1):9-31. PubMed ID: 8145563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of CCL3L1-CCR5 genotypes in the epidemic spread of HIV-1 and evaluation of vaccine efficacy.
    Kulkarni H; Marconi VC; Agan BK; McArthur C; Crawford G; Clark RA; Dolan MJ; Ahuja SK
    PLoS One; 2008; 3(11):e3671. PubMed ID: 18989363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential future impact of a partially effective HIV vaccine in a southern African setting.
    Phillips AN; Cambiano V; Nakagawa F; Ford D; Lundgren JD; Roset-Bahmanyar E; Roman F; Van Effelterre T
    PLoS One; 2014; 9(9):e107214. PubMed ID: 25207973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV epidemic in Asia: optimizing and expanding vaccine development.
    Nitayaphan S; Ngauy V; O'Connell R; Excler JL
    Expert Rev Vaccines; 2012 Jul; 11(7):805-19. PubMed ID: 22913258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco.
    Blower SM; McLean AR
    Science; 1994 Sep; 265(5177):1451-4. PubMed ID: 8073289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Knowledge about vaccines and willingness to participate in preventive HIV vaccine trials: a population-based study, Rakai, Uganda.
    Kiwanuka N; Robb M; Kigozi G; Birx D; Philips J; Wabwire-Mangen F; Wawer MJ; Nalugoda F; Sewankambo NK; Serwadda D; Gray RH
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):721-5. PubMed ID: 15167291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The modelling of dynamic ascariasis infectivity and prevalence in foci of invasion].
    Suslov IM; Romanenko NA; Abdulazizov AI; Sabgaĭda TP
    Med Parazitol (Mosk); 1993; (3):9-12. PubMed ID: 8041326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.
    Herbeck JT; Peebles K; Edlefsen PT; Rolland M; Murphy JT; Gottlieb GS; Abernethy N; Mullins JI; Mittler JE; Goodreau SM
    Vaccine; 2018 Jan; 36(4):514-520. PubMed ID: 29241646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.